Samsung just dropped $2.18B on peptides and RMTG is sitting here at 8 cents

{"summary": "Author argues RMTG is undervalued at 8 cents because Samsung Biologics' $2.18B PolyPeptide acquisition validates the peptide/GLP-1 sector and RMTG's Q2 revenue grew 309% YoY with 64% gross margins and positive operating income.", "reason": "The author provides a clear investment thesis for RMTG based on sector growth, Q2 financial performance, and a specific revenue catalyst for Q3.", "ideas": [{"symbol": "RMTG", "direction": "long", "thesis": "Author argues Samsung Biologics' $2.18B acquisition of PolyPeptide Group validates the peptide and GLP-1 market, and RMTG is already operating in that same sector through Cellgenic and ISSCA. Q2 revenue of $4.02M was up 309% YoY with 64% gross margins and $565k operating income, which the author believes makes the debt manageable via real cash flow rather than dilution. The stated catalyst is Q3 revenue around $8M over the next few months, which the author expects to draw attention to the fundamentals. Main risk is the scary debt on the balance sheet, though the author argues profitability changes the dynamic.", "thesis_short": "RMTG peptide growth validated by Samsung deal", "quote": "Samsung Biologics just dropped like 2.18 billion dollars to buy a Swiss peptide company PolyPeptide Group its the biggest overseas acquisition theyve ever done and they did it specifically for the peptide and glp1 market", "confidence": 0.7, "sentiment": 0.8, "timeframe": "next few months"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}